Table 3.
Characteristics of allogeneic HCT for B-ALL following lenalidomide treatment for MM
| ID# | Sex | Age at ALL dx (y) | Best response before HCT | HCT donor (if HCT) | CD34 selection? (if HCT) | Conditioning intensity | Conditioning regimen |
|---|---|---|---|---|---|---|---|
| 01 | F | 66 | MRD+ CR | MUD | N | RIC | Flu/Bu |
| 02 | M | 66 | MRD− CR | MRD | N | RIC | Flu/Mel |
| 03 | M | 50 | CR | MRD | Y | MAC | Total body irradiation/cyclophosphamide/thiotepa |
| 05 | M | 64 | MRD− CR | MUD | N | RIC | Flu/Mel |
| 06 | M | 63 | MRD− CR | MRD | N | RIC | Flu/Mel |
| 09 | M | 64 | MRD− CR | Haploidentical | N | MAC | Flu/Mel/thiotepa |
| 11 | M | 60 | MRD+ CR | MMUD | N | MAC | Flu/Bu |
| 13 | F | 65 | MRD− CR | MUD | N | RIC | Flu/Mel |
| 14 | M | 64 | MRD− CR | MUD | N | RIC | Flu/Mel |
| 18 | F | 68 | MRD− CR | MUD | N | RIC | Flu/Mel |
| 21 | F | 64 | MRD− CR | MUD | N | RIC | Flu/Mel |
| 25 | F | 65 | MRD− CR | MUD | Y | RIC | Flu/Bu |
| 29 | F | 68 | MRD− CR | MUD | Y | RIC | Flu/Bu |
Bu, busulfan; Flu, fludarabine; MAC, myeloablative conditioning; Mel, melphalan.